Clinical data were extracted from the STAMPEDE-H trial.10 This multicenter randomized clinical trial assessed 2061 men with newly diagnosed metastatic prostate cancer who were randomized to receive standard-of-care ADT with or without PRT. Prostate radiation therapy was 55 Gy in 20 daily fractions of 2.75 Gy for 4 weeks or 36 Gy in 6 consecutive weekly fractions of 6 Gy. Among 819 patients with low-metastatic burden (≤4 bony sites and the absence of visceral metastases), OS was improved using either fractionation regimen (HR, 0.68; 95% CI, 0.52–0.90; P = .007). Three-year survival was 73% in the control group vs 81% in the PRT group.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.